Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

7 treatments under study, led by Standard Dosing Of Labetalol

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 67/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 4 (2)

Trial Status

Terminated2
Completed2

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05096728CompletedPrimary

Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)

NCT04474704Not ApplicableCompletedPrimary

Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia

NCT03872336Phase 4TerminatedPrimary

Acute Labetalol Use in Preeclampsia

NCT03877692Phase 4TerminatedPrimary

Acute Control of Chronic Hypertension

Showing all 4 trials

Research Network

Common Treatments

  • Standard Dosing Of Labetalol1
  • Standard Of Care1
  • Cheetah Noninvasive Cardiac Monitoring System1
  • Nifedipine1
  • Current Standard Of Care1

Active Sponsors

  • Albany Medical College2
  • Ohio State University2

Top Investigators

Related Conditions

  • Chronic Hypertension In Obstetric Context1

Activity Timeline